Transcode Therapeutics Inc.
13F holders, Q4 2024 (December 31)5holders
$3.37avg. 13F price*
At the end of Q4 2024, 5 institutions reported holding Transcode Therapeutics Inc. in their 13F filings. The largest holders were UBS Group AG ($29K), Tower Research Capital LLC (TRC) ($3K) and Morgan Stanley ($1K).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L402
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $33K |
| Exits | 0 | $0 |
Ownership 5 holders
| UBS Group AG | 0.00% | New | 8,676 | $29K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 926 | $3K |
| Morgan Stanley | 0.00% | New | 304 | $1K |
| Bank of America Corp. | 0.00% | New | 4 | $13 |
| Danske Bank A/S | 0.00% | New | 1 | $3 |
"% of holder's portfolio" is TRANSCODE THERAPEUTICS INC's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.